Advertisement

Liver Involvement in Rheumatic Diseases

  • Atsushi TakahashiEmail author
  • Hiromasa Ohira
Chapter

Abstract

Liver dysfunction may be caused by various factors such as viruses, disease treatments, alcohol use, and metabolic or autoimmune diseases. The associations between rheumatic diseases and the liver are complex, because rheumatic diseases target multiple systemic organs, including the liver. In addition, both treatment with immunosuppressants and secondary viral infections can cause liver dysfunction. Although liver dysfunction in rheumatic diseases is usually mild, liver failure has been reported in some cases. Therefore, understanding the characteristics of liver failure that may occur with different rheumatic diseases is essential for the treatment of these diseases. Clinicians must consider and treat liver dysfunction in patients with a rheumatic disease with both disorders in mind.

Keywords

Liver dysfunction Rheumatic diseases Image findings Histological findings Autoimmune hepatitis Primary biliary cholangitis Viral infection Fatty liver Macrophage activation syndrome 

References

  1. 1.
    Kojima H, Uemura M, Sakurai S, et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol. 2002;37:617–25.CrossRefGoogle Scholar
  2. 2.
    Zheng RH, Wang JH, Wang SB, et al. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J (Engl). 2013;126:260–6.Google Scholar
  3. 3.
    Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69:187–94.CrossRefGoogle Scholar
  4. 4.
    Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med. 1984;53:401–9.Google Scholar
  5. 5.
    Luangjaru S, Kullavanijaya P. Gastrointestinal and hepatobiliary manifestations in systemic lupus erythematosus. J Med Assoc Thail. 2005;88:71–5.Google Scholar
  6. 6.
    Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008;35:2159–64.CrossRefGoogle Scholar
  7. 7.
    Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol. 2010;28:504–10.Google Scholar
  8. 8.
    Her M, Lee Y, Jung E, Kim T, Kim D. Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int. 2011;31:79–84.  https://doi.org/10.1007/s00296-009-1237-4.CrossRefGoogle Scholar
  9. 9.
    Huang D, Aghdassi E, Su J, Mosko J, et al. Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. J Rheumatol. 2012;39:254–61.  https://doi.org/10.3899/jrheum.110310.CrossRefGoogle Scholar
  10. 10.
    Takahashi A, Abe K, Saito R, et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013;52:1461–5.CrossRefGoogle Scholar
  11. 11.
    Takahashi A, Abe K, Yokokawa J, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092–7.CrossRefGoogle Scholar
  12. 12.
    Fernandes L, Sullivan S, McFarlane IG, et al. Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis. Ann Rheum Dis. 1979;38:501–6.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Spooner RJ, Smith DH, Bedford D, Beck PR. Serum gamma-glutamyltransferase and alkaline phosphatase in rheumatoid arthritis. J Clin Pathol. 1982;35:638–41.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Lowe JR, Pickup ME, Dixon JS, et al. Gamma glutamyl transpeptidase levels in arthritis: a correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1978;37:428–31.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Akesson A, Berglund K, Karlsson M. Liver function in some common rheumatic disorders. Scand J Rheumatol. 1980;9:81–8.CrossRefGoogle Scholar
  16. 16.
    Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren’s syndrome. Br J Rheumatol. 1994;33:745–8.CrossRefGoogle Scholar
  17. 17.
    Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjögren’s syndrome. J Hepatol. 1994;20:354–8.CrossRefGoogle Scholar
  18. 18.
    Montaño-Loza AJ, Crispín-Acuña JC, Remes-Troche JM, Uribe M. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren’s syndrome. Ann Hepatol. 2007;6:150–5.Google Scholar
  19. 19.
    Chen J. Liver, gall and pancreas. In: Liu TH, Liu TH, Li WH, editors. Diagnostic pathology. Beijing: People Health Press; 1995. p. 242.Google Scholar
  20. 20.
    Ebert EC, Hagspiel KD, Nagar M, Schlesinger N. Gastrointestinal involvement in polyarteritis nodosa. Clin Gastroenterol Hepatol. 2008;6(9):960–6.CrossRefGoogle Scholar
  21. 21.
    Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991;70:118–36.CrossRefGoogle Scholar
  22. 22.
    Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine. 2002;81:194–200.CrossRefGoogle Scholar
  23. 23.
    Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.CrossRefGoogle Scholar
  24. 24.
    Cagatay Y, Gul A, Cagatay A, et al. Adult-onset Still’s disease. Int J Clin Pract. 2009;63:1050–5.CrossRefGoogle Scholar
  25. 25.
    Zhu G, Liu G, Liu Y, Xie Q, Shi G. Liver abnormalities in adult onset Still’s disease: a retrospective study of 77 Chinese patients. J Clin Rheumatol. 2009;15:284–8.CrossRefGoogle Scholar
  26. 26.
    Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29:1015–9.CrossRefGoogle Scholar
  27. 27.
    Colina M, Zucchini W, Ciancio G, et al. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011;41:279–85.CrossRefGoogle Scholar
  28. 28.
    Chen PD, Yu SL, Chen S, Weng XH. Retrospective study of 61 patients with adult-onset Still’s disease admitted with fever of unknown origin in China. Clin Rheumatol. 2012;31:175–81.CrossRefGoogle Scholar
  29. 29.
    Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9.CrossRefGoogle Scholar
  30. 30.
    Mehrpoor G, Owlia MB, Soleimani H, Ayatollahi J. Adult-onset Still’s disease: a report of 28 cases and review of the literature. Mod Rheumatol. 2008;18:480–5.CrossRefGoogle Scholar
  31. 31.
    Ohira H, Abe K, Takahashi A. Involvement of the liver in rheumatic disease. Clin J Gastroenterol. 2012;5:9–14.CrossRefGoogle Scholar
  32. 32.
    Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2016;68:566–76.CrossRefGoogle Scholar
  33. 33.
    Aida S. Alkaline phosphatase isoenzyme activities in rheumatoid arthritis: hepatobiliary enzyme dissociation and relation to disease activity. Ann Rheum Dis. 1993;52:511–6.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366–73.CrossRefGoogle Scholar
  35. 35.
    Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:123–9.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Grover S, Rastogi A, Singh J, Rajbongshi A, Bihari C. Spectrum of histomorphologic findings in liver in patients with SLE: a review. Hepat Res Treat. 2014;2014:562979.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Bae CB, Jung JY, Kim HA, Suh CH. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore). 2015;94:e451.CrossRefGoogle Scholar
  38. 38.
    Monoe K, Kanno Y, Saito H, et al. A case of hepatocellular carcinoma associated with mixed connective tissue disease. Nihon Shokakibyo Gakkai Zasshi. 2007;104:568–72.Google Scholar
  39. 39.
    Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol. 1986;39:183–8.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Berzigotti A, Frigato M, Manfredini E, et al. Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus. World J Gastroenterol. 2011;17:4503–8.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Folomeev M, Dougados M, Beaune J, Kouyoumdjian JC, Nahoul K, Amor B, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992;1:191–5.CrossRefGoogle Scholar
  42. 42.
    Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw. 2001;12:445–52.Google Scholar
  43. 43.
    Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus. 2002;11:348–55.CrossRefGoogle Scholar
  44. 44.
    Bichile T, Petri M. Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. Curr Opin Rheumatol. 2014;26:111–7.CrossRefGoogle Scholar
  45. 45.
    Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28:1–8.CrossRefGoogle Scholar
  46. 46.
    Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015;168:317–27.CrossRefGoogle Scholar
  47. 47.
    Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol. 2005;53:199–207.CrossRefGoogle Scholar
  48. 48.
    Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer. 2001;92:2023–9.CrossRefGoogle Scholar
  49. 49.
    Avlonitis VS, Linos D. Primary hepatic lymphoma: a review. Eur J Surg. 1999;165:725–9.CrossRefGoogle Scholar
  50. 50.
    Yoshida Y, Takahashi Y, Yamashita H, et al. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:763–5.CrossRefGoogle Scholar
  51. 51.
    Tatsumi G, Ukyo N, Hirata H, Tsudo M. Primary hepatic lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Case Rep Hematol. 2014;2014:460574.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Kikuma K, Watanabe J, Oshiro Y, et al. Etiological factors in primary hepatic B-cell lymphoma. Virchows Arch. 2012;460:379–87.PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Takasumi M, Okai K, Asano T, et al. A case of methotrexate-associated lymphoproliferative disorder diagnosed by liver biopsy. Nihon Shokakibyo Gakkai Zasshi. 2015;112:115–22.Google Scholar
  54. 54.
    Alanazi T, Alqahtani M, Al Duraihim H, et al. Hepatic vasculitis mimicking liver abscesses in a patient with systemic lupus erythematosus. Ann Saudi Med. 2009;29:474–7.PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythematosus. J Rheumatol. 1981;8:752–9.Google Scholar
  56. 56.
    Mukai M, Bohgaki T, Notoya A, et al. Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus. Lupus. 2000;9:74–7.CrossRefGoogle Scholar
  57. 57.
    Liu Y, Yu J, Oaks Z, et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. Clin Immunol. 2015;160:319–27.PubMedCentralCrossRefPubMedGoogle Scholar
  58. 58.
    Ambrosino P, Lupoli R, Spadarella G, et al. Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of literature studies. J Gastrointestin Liver Dis. 2015;24:25–34, 3 p following 34.Google Scholar
  59. 59.
    Oaks Z, Winans T, Caza T, et al. Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice. Arthritis Rheumatol. 2016;68:2728–39.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Fang X, Zaman MH, Guo X, et al. Role of hepatic deposited immunoglobulin G in the pathogenesis of liver damage in systemic lupus erythematosus. Front Immunol. 2018;9:1457.PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Abe K, Takahashi A, Nozawa Y, et al. The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol. 2014;47:162–8.CrossRefGoogle Scholar
  62. 62.
    Thompson PW, Houghton BJ, Clifford C, et al. The source and significance of raised serum enzymes in rheumatoid arthritis. Q J Med. 1990;76:869–79.Google Scholar
  63. 63.
    Malnick S, Melzer E, Sokolowski N, Basevitz A. The involvement of the liver in systemic diseases. J Clin Gastroenterol. 2008;42:69–80.CrossRefGoogle Scholar
  64. 64.
    Tojo J, Ohira H, Abe K, et al. Autoimmune hepatitis accompanied by systemic lupus erythematosus. Intern Med. 2004;43:258–62.CrossRefGoogle Scholar
  65. 65.
    Ohira H, Takiguchi J, Rai T, et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res. 2004;28:137–9.CrossRefGoogle Scholar
  66. 66.
    Takahashi A, Arinaga-Hino T, Ohira H, et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol. 2017;52:631–40.CrossRefGoogle Scholar
  67. 67.
    Abe M, Mashiba T, Zeniya M, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–41.CrossRefGoogle Scholar
  68. 68.
    Oka H. The survey of autoimmune hepatitis in Japan. Annual Report of the Study Group on Severe Hepatitis. Japanese Ministry of Health and Welfare. 1988;235–41. (Japanese).Google Scholar
  69. 69.
    Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44:208–13.CrossRefGoogle Scholar
  70. 70.
    Iwai M, Harada Y, Ishii M, et al. Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin Rheumatol. 2003;22:234–6.CrossRefGoogle Scholar
  71. 71.
    Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010;12:R143.PubMedCentralCrossRefPubMedGoogle Scholar
  72. 72.
    Toulemonde G, Scoazec JY, Miossec P. Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: an open label proof of concept study. Ann Rheum Dis. 2012;71:1423–4.CrossRefGoogle Scholar
  73. 73.
    Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9:188–93.CrossRefGoogle Scholar
  74. 74.
    Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21:7584–8.PubMedCentralCrossRefPubMedGoogle Scholar
  75. 75.
    Ramos-Casals M, Sánchez-Tapias JM, Parés A, et al. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren’s syndrome. J Rheumatol. 2006;33:1593–9.Google Scholar
  76. 76.
    Karp JK, Akpek EK, Anders RA. Autoimmune hepatitis in patients with primary Sjögren’s syndrome: a series of two-hundred and two patients. Int J Clin Exp Pathol. 2010;3:582–6.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Fragoulis GE, Skopouli FN, Selmi C, Gershwin ME. Liver involvement in primary Sjögren’s syndrome. In: Ramos-Casals M, Stone J, Moutsopoulos H, editors. Sjögren’s syndrome. Diagnosis and therapeutics. London: Springer; 2012. p. 237–46.Google Scholar
  78. 78.
    Efe C, Wahlin S, Ozaslan E, et al. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol. 2012;24:531–4.CrossRefGoogle Scholar
  79. 79.
    Matsumoto T, Morizane T, Aoki Y, et al. Autoimmune hepatitis in primary Sjogren’s syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren’s syndrome. Pathol Int. 2005;55:70–6.CrossRefGoogle Scholar
  80. 80.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.CrossRefGoogle Scholar
  81. 81.
    Hirohara J. National surveys of primary biliary cirrhosis (PBC) in Japan. Annual Report of the intractable Liver and Biliary Diseases Study Group of Japan. Japanese Ministry of Health, Labour and Welfare. 2016;59–65. (Japanese). https://mhlw-grants.niph.go.jp.
  82. 82.
    De Santis M, Crotti C, Selmi C. Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol. 2013;27:543–51.CrossRefGoogle Scholar
  83. 83.
    Wang L, Zhang FC, Chen H, et al. Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol. 2013;19:5131–7.PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004;97:397–406.CrossRefGoogle Scholar
  85. 85.
    Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194–202.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis. 2001;60:1046–9.PubMedCentralCrossRefPubMedGoogle Scholar
  87. 87.
    Hatzis GS, Fragoulis GE, Karatzaferis A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren’s syndrome. J Rheumatol. 2008;35:2012–6.Google Scholar
  88. 88.
    Zeron PB, Retamozo S, Bové A, et al. Diagnosis of liver involvement in primary Sjögren syndrome. J Clin Transl Hepatol. 2013;1:94–102.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Assassi S, Fritzler MJ, Arnett FC, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009;36:2250–6.PubMedCentralCrossRefPubMedGoogle Scholar
  90. 90.
    Hansen BU, Eriksson S, Lindgren S. High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies. Scand J Gastroenterol. 1991;26:707–13.CrossRefGoogle Scholar
  91. 91.
    Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med. 1992;31:1348–55.CrossRefGoogle Scholar
  92. 92.
    Rigamonti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388–94.PubMedCentralCrossRefPubMedGoogle Scholar
  93. 93.
    Tojo J, Ohira H, Suzuki T, et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res. 2002;22:187–95.CrossRefGoogle Scholar
  94. 94.
    Saito H, Takahashi A, Abe K, et al. Two cases of primary biliary cirrhosis associated with systemic lupus erythematosus. Kanzo. 2011;52:169–75.CrossRefGoogle Scholar
  95. 95.
    Picceli VF, Skare TL, Nisihara R, et al. Spectrum of autoantibodies for gastrointestinal autoimmune diseases in systemic lupus erythematosus patients. Lupus. 2013;22:1150–5.CrossRefGoogle Scholar
  96. 96.
    Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–7.CrossRefGoogle Scholar
  97. 97.
    Shizuma T, Kuroda H. A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus. Intern Med. 2011;50:321–4.CrossRefGoogle Scholar
  98. 98.
    Hammami S, Chaabane N, Mahmoudi H, Bdioui F, Saffar H. Late-onset systemic lupus erythematosus-associated primary biliary cirrhosis. Int Arch Med. 2013;6:3.PubMedCentralCrossRefPubMedGoogle Scholar
  99. 99.
    Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42:658–60.PubMedCentralCrossRefPubMedGoogle Scholar
  100. 100.
    Radovanović-Dinić B, Tešić-Rajković S, Zivkovic V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int. 2018;38:715–24.CrossRefGoogle Scholar
  101. 101.
    Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502–12.CrossRefGoogle Scholar
  102. 102.
    Datta A, Deodhar SD, Datta U, Sehgal S. Non-organ specific & organ specific antibodies in rheumatoid arthritis. Indian J Med Res. 1990;92:228–32.Google Scholar
  103. 103.
    Zurgil N, Bakimer R, Moutsopoulos HM, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol. 1992;12:201–9.CrossRefGoogle Scholar
  104. 104.
    Mouritsen S, Demant E, Permin H, Wiik A. High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases. Clin Exp Immunol. 1986;66:68–76.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact? J Gastroenterol Hepatol. 2007;22:454–5.CrossRefGoogle Scholar
  106. 106.
    Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis. 2012;2012:391567.PubMedCentralCrossRefPubMedGoogle Scholar
  107. 107.
    Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150:1599–608.CrossRefGoogle Scholar
  108. 108.
    Brito-Zerón P, Gheitasi H, Retamozo S, et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. Arthritis Res Ther. 2015;17:250.PubMedCentralCrossRefPubMedGoogle Scholar
  109. 109.
    Toussirot E, Le Huédé G, Mougin C, Balblanc JC, Bettinger D, Wendling D. Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren’s syndrome and hepatitis C virus infection. J Rheumatol. 2002;29:2382–5.Google Scholar
  110. 110.
    Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A. 1997;94:233–6.PubMedCentralCrossRefPubMedGoogle Scholar
  111. 111.
    Patel R, Mikuls TR, Richards JS, et al. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection. Arthritis Care Res (Hoboken). 2015;67:467–74.CrossRefGoogle Scholar
  112. 112.
    Morito T, Nishimagi T, Onizawa N, et al. Studies on complement of sera with liver diseases. Kanzo. 1977;45:925–35.CrossRefGoogle Scholar
  113. 113.
    Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents. Rheum Dis Clin North Am. 2017;43:123–32.CrossRefGoogle Scholar
  114. 114.
    Lee YH, Ji JD, Yeon JE, et al. Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis. 1998;57:728–31.PubMedCentralCrossRefPubMedGoogle Scholar
  115. 115.
    Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777–82.CrossRefGoogle Scholar
  116. 116.
    Sise ME, Bloom AK, Wisocky J, Lin MV, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–17.CrossRefGoogle Scholar
  117. 117.
    Watanabe R, Ishii T, Kobayashi H, et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med. 2014;233:129–33.CrossRefGoogle Scholar
  118. 118.
    Tsai WP, Chen MH, Lee MH, et al. Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. Rheumatol Int. 2012;32:2901–8.CrossRefGoogle Scholar
  119. 119.
    Zhang J, Dou Y, Zhong Z, et al. Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients. Lupus. 2014;23:889–97.CrossRefGoogle Scholar
  120. 120.
    Komura T, Ohta H, Nakai R, et al. Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab. Intern Med. 2016;55:1923–297.CrossRefGoogle Scholar
  121. 121.
    Bauer H, Luxembourger C, Gottenberg JE, et al. Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore). 2015;94:e675.CrossRefGoogle Scholar
  122. 122.
    Sugawara N, Yawata A, Takahashi K, Abe N, Arai M. The third case of fulminant hepatitis associated with “Kitami/Abashiri train” of hepatitis E virus genotype 4. Kanzo. 2009;50:473–4.CrossRefGoogle Scholar
  123. 123.
    Horizon AA, Wallace DJ. Risk: benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3:273–8.CrossRefGoogle Scholar
  124. 124.
    Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16:5651–61.PubMedCentralCrossRefPubMedGoogle Scholar
  125. 125.
    Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127:303–14.PubMedCentralCrossRefPubMedGoogle Scholar
  126. 126.
    Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23:225–35.CrossRefGoogle Scholar
  127. 127.
    Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275–9.Google Scholar
  128. 128.
    Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009;27:1017–25.Google Scholar
  129. 129.
    Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. Sci World J. 2014;2014:823763.CrossRefGoogle Scholar
  130. 130.
    Hakim NS, Kobienia B, Benedetti E, Bloomer J, Payne WD. Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. Int Surg. 1998;83:224–5.Google Scholar
  131. 131.
    Mori S, Arima N, Ito M, et al. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One. 2018;13:e0203084.PubMedCentralCrossRefPubMedGoogle Scholar
  132. 132.
    Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.CrossRefGoogle Scholar
  133. 133.
    Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710–23.CrossRefGoogle Scholar
  134. 134.
    Miyata M, Kuroda M, Unakami M, et al. Validation of the Fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Mod Rheumatol. 2018;31:1–20.  https://doi.org/10.1080/14397595.2018.1542962.CrossRefGoogle Scholar
  135. 135.
    Deane S, Selmi C, Teuber SS, Gershwin ME. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol. 2010;153:109–20.CrossRefGoogle Scholar
  136. 136.
    Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139:713–27.CrossRefGoogle Scholar
  137. 137.
    Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106:561–6.CrossRefGoogle Scholar
  138. 138.
    Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2016;75:481–9.CrossRefGoogle Scholar
  139. 139.
    Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefGoogle Scholar
  140. 140.
    Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387–90.CrossRefGoogle Scholar
  141. 141.
    Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.CrossRefGoogle Scholar
  142. 142.
    Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev. 2004;3:69–75.CrossRefGoogle Scholar
  143. 143.
    Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014;66:2297–307.PubMedCentralCrossRefPubMedGoogle Scholar
  144. 144.
    Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyFukushima Medical University School of MedicineFukushimaJapan

Personalised recommendations